News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Cardiome Pharma Corp. Says Heart Drug Program Delayed, Shares Fall
August 11, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Aug 11 (Reuters) - Canada's Cardiome Pharma Corp (COM.TO) said the development of its key drug to treat irregular heart beats will be delayed, sending its shares down as much as 18 percent on Wednesday morning.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 2
Phase 3
FDA
Approvals
MORE ON THIS TOPIC
Immunology and inflammation
Nektar’s Rezpeg Differentiates in Atopic Dermatitis With Durable, Deep Responses in Mid-Stage
February 11, 2026
·
2 min read
·
Tristan Manalac
Vaccines
FDA Refuses To Review Moderna’s mRNA Flu Vaccine, Claims Trial Inadequacies
February 11, 2026
·
4 min read
·
Tristan Manalac
Podcast
Weight Loss Drama Compounds on Heels of Novo, Lilly Earnings, Plus Gene Therapy News
February 11, 2026
·
1 min read
·
Jef Akst
Immunology and inflammation
Evommune Soars as Dermatitis Treatment Rivals Dupixent in Mid-Stage Trial
February 10, 2026
·
1 min read
·
Dan Samorodnitsky
